- Home
- NSTS vs ANL Comparison
NSTS vs ANL Comparison
Compare NSTS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NSTS | ANL |
|---|---|---|
| Founded | 1921 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NSTS | ANL |
|---|---|---|
| Price | $11.71 | $1.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.5K | ★ 13.2K |
| Earning Date | 11-13-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $0.88 |
| 52 Week High | $13.32 | $2.99 |
Technical Indicators
Market Signals| Indicator | NSTS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 67.47 | 22.30 |
| Support Level | $11.14 | $1.32 |
| Resistance Level | $11.75 | $1.59 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 94.00 | 5.70 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.